Defining Success in IBD: Treat-to-Target
Florence Odufalu, MD
Ugo Iroku, MD, MHS
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
IBD Care Reimagined: Personalized, Proactive, and Target-Driven Management
David T. Rubin, MD
Michael Dolinger, MD, MBA
Revisiting Anti-TNFs: Role, Risks, and Real-World Considerations
Beyond One-Size-Fits-All: Individualizing First-Line IBD Treatment
Setting the Stage: Why Rethinking IBD Care Matters Now
Targeting IL-23 Pathways: Evolving Biologic Strategies in IBD
Small Molecules in IBD: JAK Inhibitors and S1P Modulators
The Future of Biologic Treatment in IBD: What’s on the Horizon
Gut-Selective Therapy: Understanding Anti-Integrins in IBD
Navigating IBD Guidelines: What Clinicians Need to Know Now
The Evolving Role of Small Molecules in IBD Care
Translating Advances into Practice: Lessons from Today’s IBD Landscape
IBD Beyond Symptoms: What Community GIs Need to Know
Targeting Inflammation in IBD: Localized vs Systemic Strategies
Remission: Can You Prove It?
David Rubin, MD
Kimberly D. Orleck, PA-C
Switching Strategies: Switch or Stay—What’s Your Call?
Brooke Hodnick, PA-C, MPAS
Loading...
We're glad to see you're enjoying Crohn's Colitis Professional… but how about a more personalized experience?
Press cancel to remain on Crohn's Colitis Professional. Press the link below or the continue button to keep going.